Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer The STIC CTC Randomized Clinical Trial
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer The STIC CTC Randomized Clinical Trial
复制标题
DOI：
10.1001/jamaoncol.2020.5660
复制
发表时间：
2020-11-05
期刊：
影响因子：
28.4
通讯作者：
Pierga, Jean-Yves
中科院分区：
文献类型：
--
作者：
Bidard, Francois-Clement;Jacot, William;Pierga, Jean-Yves
重要性选择化疗和内分泌治疗作为激素受体阳性、ERBB2(也称为HER2)阴性的转移性乳腺癌的一线治疗，通常是基于与预后不良相关的临床特征。在这种情况下，高循环肿瘤细胞(CTC)计数(=5个CTCs/7.5毫升)对总体生存和无进展生存(PFS)是一个强烈的不良预后因素。目的比较临床医生主导的治疗选择和CTC驱动的一线治疗选择的疗效。干预在CTC组，患者根据CTC计数接受化疗或内分泌治疗(化疗=5个CTCs/7.5毫升；内分泌治疗如果
IMPORTANCE The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor-positive, ERBB2 (also known as HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis. In this setting, a high circulating tumor cell (CTC) count (>= 5 CTCs/7.5 mL) is a strong adverse prognostic factor for overall survival and progression-free survival (PFS).OBJECTIVE To compare the efficacy of a clinician-driven treatment choice vs a CTC-driven choice for first-line treatment.INTERVENTIONS In the CTC arm, patients received chemotherapy or endocrine therapy according to the CTC count (chemotherapy if >= 5 CTCs/7.5 mL; endocrine therapy if